Assistant Professor
Bio
Dr. Schneider is a breast cancer researcher at Rush University Medical Center whose work focuses on enhancing immunotherapy efficacy through detailed study of the tumor microenvironment and immune system interactions. Drawing on a multidisciplinary background in infectious disease, antibody manipulation, and advanced imaging, he has developed in vivo imaging protocols to track breast cancer immunotherapeutics and modified agents such as IL15Ra-Fc to improve immune responses. His research also explores altering the tumor microenvironment to increase therapeutic effectiveness, particularly in triple-negative breast cancer. Dr. Schneider is dedicated to developing innovative, patient-tailored approaches to improve treatment outcomes.
Not all breast cancers respond to the same therapies, and patients vary in their immune response potential. This study aims to tailor immunotherapy to each patient’s individualized “immuno-fingerprint,” with the goal of maximizing treatment efficacy and improving outcomes for all breast cancer patients. This work explores biochemical modifications to the tumor microenvironment and innovative immunotherapeutics to enhance anti-cancer immunity. The ultimate goal is to advance personalized treatment strategies that reduce patient suffering and move closer to eradicating breast cancer.
Jeffrey Schneider, PhD
Rush University Medical Center
Current
Early Investigator
Lamiaa El-Shennawy, PhD
Uptake of Tumor Extracellular Vesicles for Immune Regulation in TNBC
Current
Early Investigator
Frederick Howard, MD
Predicting Breast Cancer Recurrence in the Chicagoland Area Using Artificial Intelligence
Why your gift matters
Your gift helps researchers test bold ideas, generate critical data, and take the first steps toward the next major advancement in breast cancer treatment and care.Together, we can accelerate discoveries that save lives.
